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ABSTRACT
The objective of the current study was to investigate the processability of Aquasolve™
HPMC-AS LG via hot-melt extrusion, and to examine the effect of pressurized carbon dioxide (PCO2) on the physico-mechanical properties of Efavirenz (EFA)-loaded extrudates (EXT). EFA is
as a poorly water-soluble drug and HPMC-AS LG was chosen as a carrier for this study. To
optimize the process parameters and formulations, various physical mixtures were prepared with
the following composition: EFA (30-40-50% w/w) and HPMC-AS LG (70-60-50 % w/w)
respectively. Physical mixtures were extruded through the co-rotating twin-screw extruder (16mm
Prism Euro Lab, Thermo Fisher Scientific) utilizing a standard screw configuration. P-CO2 was
injected into eight zone of extruder using a high-pressure regulator connected to flexible stainlesssteel hose with armor casing. The thermal characterization of extrudates was obtained by using
differential scanning calorimetry (DSC) and thermal gravimetric analysis (TGA). A scanning
electron microscopy (SEM) was conducted to study morphology and porosity of formulations. The
macroscopic morphology changed to a foam-like structure, resulting in increased specific surface
area, porosity and dissolution rate. Thus, HPMC-AS LG extrudates with P-CO2 injection exhibited
relatively higher dissolution rate than extrudates without P-CO2. Additionally, HPMC-AS LG was
able to physically and chemically stabilize the amorphous state of high-loading EFA in the
extrudates. The milling efficiency was improved for extrudates with P-CO2 injection due to porous
nature and morphology changes.

ii

DEDICATION
This thesis is dedicated to my dear parents, Mr. Salem Almutairi and Mrs. Sabha Almutairi,
my brothers and sisters, to my gorgeous wife Haylaa AlMutairi and five daughters, Taif, Hanin,
Ghala, Ward, and Assal for all their support, help and affection all through these years. They all
have made me what I am today with their unending encouragement and guidance in every aspect
of my life.

iii

ACKNOWLEDGMENTS
I would like to express my sincere gratitude, appreciation and thanks to my advisor Dr.
Michael A. Repka, Chair & Professor of Pharmaceutics and drug delivery, for his unyielding
support, guidance and encouragement throughout my M.S Program. It is my honor to be one of
his students and to have worked under his supervision.
I would like to thank Dr. S. Narasimha Murthy, and Dr. Samir A. Ross, to serve as a
committee member for my Master' Thesis. I could not have completed my thesis without their
help.
I would also like to thank all the faculty and staff in the Pharmacy School, especially Mrs.
Deborah King for her help and affection. I thank Dr. Dongwuk Kim, and Dr. Suresh Bandari for
their expertise and advice on my research during their Postdoc period in the department.
I am deeply thankful to all my colleagues and friends for their help, friendship and moral
support in all aspects of my life. I also appreciate the enormous support from the Saudi Arabian
Cultural Mission (SACM) and my government from the Kingdom of Saudi Arabia.

iv

TABLE OF CONTENTS
ABSTRACT ........................................................................................................................ ii
DEDICATION ................................................................................................................... iii
ACKNOWLEDGMENTS ................................................................................................. iv
TABLE OF CONTENTS .................................................................................................... v
LIST OF TABLES ............................................................................................................ vii
LIST OF FIGURES ......................................................................................................... viii
1. INTRODUCTION .......................................................................................................... 1
2. MATERIALS AND METHODS .................................................................................... 4
2.1. Materials .................................................................................................................. 4
2.2. Methods.................................................................................................................... 4
2.2.1. Thermogravimetric analysis (TGA) .................................................................. 4
2.2.2. Hot Melt Extrusion processing ......................................................................... 4
2.2.3. Physical mixture................................................................................................ 5
2.2.4. Milling Efficiency ............................................................................................. 6
2.2.5. Drug content and degradation ........................................................................... 7
2.2.6. Dissolution studies ............................................................................................ 7
2.2.7. Solid State Characterization .............................................................................. 8
2.2.7.1. Differential Scanning Calorimetry (DSC) ..................................................... 8
2.2.7.2. Powder X-ray Diffraction Measurements (PXRD)........................................ 8
2.2.7.3. Scanning electron microscopy (SEM) ........................................................... 9
v

2.2.8. Density and porosity ......................................................................................... 9
3. RESULTS AND DISCUSSION ................................................................................... 10
3.1. HME processing..................................................................................................... 10
3.2. Screening of appropriate API................................................................................. 11
3.3. Drug content and degradation ................................................................................ 12
3.4. Differential scanning calorimetry (DSC) ............................................................... 13
3.5. Powder X-ray Diffraction Measurements (PXRD)................................................ 13
3.6. Dissolution Studies ................................................................................................ 14
3.7. Scanning electron microscopy (SEM) ................................................................... 19
3.8. Density and Porosity .............................................................................................. 20
3.9. Milling Efficiency .................................................................................................. 21
BIBLIOGRAPHY ............................................................................................................. 24
VITA ................................................................................................................................. 29

vi

LIST OF TABLES
Table 1. Conditions and outcomes for optimized formulations during HME processes ............................................... 6
Table 2. Results and conditions of investigating the extruder parameters, (polymer/ drug) ratio, and the type of the
drug on HME processes with and without P-CO2 injection. ........................................................................................ 15
Table 3. Bulk, tapped, true density and porosity of pure EFA, pure HPMC-AS LG, Physical Mixture (PM) and
Extrudates (EXT) with and without P-CO2 (g/ml)....................................................................................................... 21
Table 4. Results of the Milling Efficiency ................................................................................................................... 23

vii

LIST OF FIGURES
Figure 1. Schematic representation for the set-up of the combined HME/P-CO2 techniques ....................................... 5
Figure 2. DSC thermograms of pure EFA, pure HPMC-AS LG, physical mixtures (PM) and extrudates (EXT) (with
and without P-CO2). .................................................................................................................................................... 16
Figure 3. A: PXRD diffractograms of pure crystalline EFA, B: PXRD diffractograms of pure HPMC-AS LG. C, F,
and I: PXRD diffractograms of %30, %40, and %50 EFA/ HPMC-AS LG PM. D, G, and J: PXRD diffractograms of
%30, %40, and %50 EFA/ HPMC-AS LG without-CO2. E, H, and K: PXRD diffractograms of %30, %40, and %50
EFA/ HPMC-AS LG with P-CO2. .............................................................................................................................. 17
Figure 4. In-Vitro release profile extrudates with and without P-CO2 ........................................................................ 19
Figure 5. SEM images of all Extrudates without, and with P-CO2 ............................................................................. 22

viii

1. INTRODUCTION

In the last two decades, hot melt extrusion has evolved as one of the most promising
pharmaceutical processing technology. [1]. HME technology has several advantages over
conventional pharmaceutical processing technologies including short processing time, continuous
process, does not demand the use of water or toxic organic solvents[2,3]. HME is generally utilized
for solubility enhancement[5]. HME has also revealed significant value for manufacturing various
dosage forms such as pellets, tablets, transmucosal products as well as various usages such as
controlled release formulations, targeted drug delivery including taste masking formulations.[6].
HME pharmaceutical applications have not been wholly appreciated, mainly attributed to the
complex design of HME as well as the non-predicted performance of materials during the HME
process[7].
Recently, several HME-enabled products have commercially approved, which gives this
technology more interest in the pharmaceutical industry. However, it is hard to ignore the fact that
many of pharmaceutical polymeric systems shown thermal and/or viscoelastic challenges during
HME process. Moreover, active pharmaceutical ingredients exhibit their own individual
limitations such as high melting temperatures and/or the low degradation temperatures [8].The
physicochemical properties of the active pharmaceutical ingredient (API), including the glass
transition and the melting point temperatures, the degradation temperatures, and the miscibility or
solubility of the API in the polymer carrier, have to be considered carefully, since they have a
significant effect on the hot-melt extrusion processes as well as the final output[9–12].
1

The polymer carrier system is regularly the principal component within the formulation.
Thus, the physicochemical properties of the polymer carrier including molecular weight, viscosity,
Tg, etc., can have the significant influence on HME processing conditions and the performance of
the HME drug products [13,14]. The degradation temperature and viscoelastic properties of the
polymeric carrier system are two major factors and must be well-thought-out during HME process
[15]. Therefore, the fully realizing of thermal and viscoelastic properties of the various
drug/polymer mixtures help to establish the HME processing parameters (such as extrusion
temperatures, screw speed, feeding rate, and motor load) as well as provide insight into the
properties of the final output [16].
More than 50% of common pharmaceutical polymers for HME processing could not be
processed as neat by HME. The reason of this problem attributes that those polymers reveal
viscosities exceeding the defined maximum viscosity limit within HME processing window.
Normally, this issue could be solved by plasticizing these polymers through adding the APIs, in
which reducing the viscosities to be smoothly extrudable. When the APIs can’t adequately
plasticize the polymeric carriers, in this case, it requires an alternative formulation or processing
strategies to utilize these carriers. Moreover, the feasibility of thermally unstable APIs becomes
less when the polymeric carriers processing at high temperatures during HME processing window
[8].
One of the strategies to process the polymers within acceptable processing conditions is
addition of plasticizers [17]. Typically, plasticizers perform to increase the free volume between
polymer chains, causing a depression of the Tg and the melt viscosity [18]. Normally, traditional
plasticizers are utilized in a concentration between 5–30 % w/w of the extrudable physical
mixtures[19–21]. The additional 5–30% w/w to the total weight of formulations, is a drawback,
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since that may be result in large dosage forms [17]. Therefore, it would be necessarily to find an
alternative to traditional plasticizers in pharmaceutical extrusion. Lately, supercritical carbon
dioxide (sc-CO2), and subcritical (pressurized) carbon dioxide have been investigated as temporary
plasticizer by reducing the HME processing temperatures without adding weight to the final
formulations [22,23]. It has been examined that sc-CO2, or P-CO2 act as a foaming agent [24]. Thus,
the increasing surface area and the porosity of the polymers resulting in enhanced dissolution [25].
HPMC-AS has been exhibited to be a very effective crystallization inhibitor in amorphous
solid dispersions ASDs [26,27]. HPMC-AS polymers have a Tg of 120°C, however they regularly
require extrusion temperatures in excess of 170°C, even with plasticization, to reduce the higher
motor torque due to melt viscosity[28]. Then, these facts put HPMC-AS LG a desirable candidate
for the current research to provide a fully understanding of the relationship between the physical
and mechanical properties of physical mixtures of model drug and HPMC-AS LG to assess their
suitability, as well as the correlation with the actual hot-melt extrusion process parameters. In this
current study the effect of carbon dioxide as a foaming agent was examined, and understand the
impact on the physico-mechanical properties and performance of the extrudates.
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2. MATERIALS AND METHODS
2.1. Materials

Aquasolve™ Hydroxypropyl Methylcellulose Acetate Succinate HPMC-AS LG grade and
Efavirenz (EFA), Ibuprofen (IBU), and Theophylline (THEO) were obtained as gift samples from
Ashland Inc. (Wilmington, DE). Carbon dioxide (CO2) was supplied in gas cylinders (pure clean)
from Airgas (Tupelo, MS). All other chemicals and reagents used in the present study were of
analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ).

2.2. Methods
2.2.1. Thermogravimetric analysis (TGA)

TGA studies were performed for materials EFA and HPMC-AS LG to establish processing
temperatures for extrusion and stability using a Perkin Elmer Pyris 1 TGA running Pyris manager
software (PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA).
Five to seven milligrams of the sample were weighed in an aluminum pan and heated from 25°C
to 200°C at 10°C/min heating rate under nitrogen atmosphere.
2.2.2. Hot Melt Extrusion processing

The co-rotating twin-screw intermeshing extruder (16mm Prism Euro Lab, Thermo Fisher
Scientific, Waltham, MA) was utilized to perform the HME processes. The extruder is divided into
10-barrel zones adjacent to the gravimetric feeder. Thermo Fisher Scientific standard screw
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configuration was used for this study, which consists of four conveying zones and three mixing
zones Carbon dioxide (CO2) was pressurized and injected into the extruder using a high-pressure
regulator connected to flexible stainless-steel hose with armor casing. The other end of the hose
was connected to the four-way connection, fitted with a pressure gauge, bleed valve, check valve
(ball type for unidirectional flow of gas), with the latter being connected to the injection port at
eight zone (conveying zone) of the extruder (Figure 1). Metering of P-CO2 was regulated using
the regulator knob. The preliminary studies were conducted to determine the processing
temperature of pure polymer over temperature range of 140 to 190 °C with 75 & 100 rpm. At 190
°C extrusion was investigated in the presence of P-CO2. Similarly, the extrusion was investigated
at 20%, 30%, 40% and 50% drug load with and without P-CO2 (data not shown).

Figure 1. Schematic representation for the set-up of the combined HME/P-CO2 techniques

2.2.3. Physical mixture

After optimizing the HME process parameters and formulation, various physical mixtures
were prepared with the following composition: EFA (30-40-50% w/w) and HPMC-AS LG (7060-50% w/w), respectively. The mixtures were blended using a V-shell blender (Maxiblend,
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GlobePharma) at 25 rpm for 15 min. All the formulations mentioned in (Table 1) were studied and
successfully extruded at the employed processing conditions.
Table 1. Conditions and outcomes for optimized formulations during HME processes
Formulations

30% EFA/ 70% HPMC-AS LG EXT
30% EFA/ 70% HPMC-AS LG EXT
40% EFA/ 60% HPMC-AS LG EXT
40% EFA/ 60% HPMC-AS LG EXT
50% EFA/ 50% HPMC-AS LG EXT
50% EFA/ 50% HPMC-AS LG EXT
30% EFA/ 70% HPMC-AS LG EXT
30% EFA/ 70% HPMC-AS LG EXT
40% EFA/ 60% HPMC-AS LG EXT
40% EFA/ 60% HPMC-AS LG EXT
50% EFA/ 50% HPMC-AS LG EXT
50% EFA/ 50% HPMC-AS LG EXT

Processing
Temperature
(°C)
140
140
140
140
140
140
150
150
150
150
150
150

Screw
Speed
(rpm)
100
100
100
100
100
100
75
75
75
75
75
75

Barrel
Torque
(%)
46
46
33
33
27
27
25-30
25-30
20-25
20-25
13-20
13-20

P-CO2 (PSI)

300-400
300-400
300-400
250-300
250-300
250-300
-

P-CO2
Injection
Zone
Zone 8
Zone 8
Zone 8
Zone 8
Zone 8
Zone 8
-

 These formulations were selected for further studies based on preliminary studies results.

2.2.4. Milling Efficiency

Prior to analysis, the HME extrudates were milled using a Fitz lab scale mill (Model L1A,
Fitzpatrick, Perth Amboy, NJ) and particle size distribution and milling efficiency was studied
using a vibrating sieve shaker (Gilson, performer III SS-3). The fraction below 600 m was utilized
for further investigation. To study the milling efficiency of formulations before and after injection
of P-CO2, 25 g of each melt extruded sample was milled for 3 min, 3000 rpm with a Fitz laboratory
mill and particle size distribution was estimated using the vibrating sieve method. A set of sieves
with known mesh size (respectively 75, 125, 250, 420, 600 and 840 m) and known tar weight,
was placed on top of each other and known amount of the powder was placed in the top sieve. The
whole stack was placed on a vibrating plate for 10 min at an amplitude of 1.5 mm after which each
sieve was weight to obtain a particle size average distribution.
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2.2.5. Drug content and degradation

UV analysis was conducted to determine the uniformity of weight, drug content and
degradation after extrusion with or without P-CO2 injection. The assay methods detailed in the
USP were performed. The EFA content in the extrudates was determined by dissolving the
contents in phosphate buffer solution (pH 6.8) and assayed spectrophotometrically against a blank
comprising the buffer solution. The analysis was performed by UV spectrophotometer at 247 nm
(Genesys 6, Thermo Fisher Scientific, Madison, WI, USA); a value at which the absorbance of the
polymer is negligible. The percent drug content was compared to the calculated value. The
experimental value was the average of triplicate.

2.2.6. Dissolution studies

In-Vitro dissolution testing was conducted on milled and 40# sieved extrudates samples
and compared with a pure crystalline EFA. A USP dissolution apparatus II (Hanson SR8; Hanson
Research, Chatsworth, CA, USA) was utilized with pH 6.8 phosphate buffer, at 37±0.5 °C, using
a paddle rotating at 50 rpm, for 2 h. At predetermined time points, 2 mL of an aliquot was
withdrawn and filtered through a filter tip 10 µm (Rockwood, TN, USA) and replaced with an
equal volume of fresh dissolution medium after each sampling. EFA was assayed by UV
spectrophotometer

maximum wavelength of 247 nm (Genesys 6, Thermo Fisher Scientific,

Madison, WI, USA). All dissolution tests were carried out in triplicate and the mean and SD were
reported. Student’s t-test was used for statistical analysis.

7

2.2.7. Solid State Characterization

The nature of EFA in the extrudates was determined by using differential scanning
calorimetry (DSC) and confirmed by powder x-ray diffraction (PXRD).
2.2.7.1. Differential Scanning Calorimetry (DSC)

The nature of pure EFA, pure HPMC-AS LG, physical mixture and its corresponding
extrudates was assessed by DSC. The analysis was preformed using a DSC (TA instruments DSC
25 Discovery series) coupled with a refrigerated cooling system. Samples of between 4 and 8 mg
were weighed out using a Mettler Toledo scale. Samples were then placed in non-perforated
aluminum pans, which were crimped before testing, with an empty crimped aluminum pan being
used as a reference cell. Calorimetry scans were carried out from 50 to 200 °C for each sample.
All DSC measurements were carried out at a scanning rate of 10 °C/min. Volatiles were removed
from the purging head with nitrogen at a rate of 20 ml/min. Calibration of the instrument was
preformed using indium as standard. After each scan was completed the melting points were
analyzed and Trois manager software was used for the data analysis.
2.2.7.2. Powder X-ray Diffraction Measurements (PXRD)

The confirmation of crystallinity degree of pure EFA, pure HPMC-AS LG, EFA in the
physical mixture and respective extrudates was investigated using, powder X-ray diffraction
(PXRD) analyses using a Bruker D8 Focus X-ray diffractometer operated at voltage of 40 kV and
a current of 40 mA. Powder was packed into the sample holder. Data for each sample were
collected in the 2Θ angle range of 4–40° over 10 min in continuous detector scan mode. The
process parameters were set as scan-step size of 0.02° (2Θ) and scan-step time of 0.3 s.
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2.2.7.3. Scanning electron microscopy (SEM)

The morphological characteristics and degree of porosity of extrudates at different drug
loads of 30, 40 and 50 % with and without P-CO2 treatment was studied using SEM (JEOL JSM5600) that was operated at an accelerating voltage of 5 kV under analysis mode. Each specimen
was fixed by conductive double-sided carbon adhesive tape and gold-sputter coated by a
Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high-vacuum evaporator
prior to the test to avoid electrostatic charging. Four magnificent (25, 50, 100, 250) were employed
to give more accurate and clear understanding of results.
2.2.8. Density and porosity

True density of powdered extrudates for all the formulations as well as the pure polymer
with and without P-CO2 was measured utilizing Micromeritics AccuPyc 1330 Gas pycnometer
S/N-4011 (Norcross, GA). Prior to each run, calibration was performed. The sample was filled in
10-cm3 sample cup and the weight of the sample was noted. True density was measured at an
equilibration rate of 0.0050 psig/min and the number of purges was set to 10. Bulk and tapped
density was calculated by measuring the volume of a 5 g milled extrudates in a 10 mL graduated
cylinder. Porosity was calculated by the following equation [29].
% 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 = 1 −

𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
× 100
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
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3. RESULTS AND DISCUSSION
3.1. HME processing

The physicochemical properties of the API, and the polymeric carrier have to be
considered carefully, since they have a significant effect on the hot-melt extrusion processes as
well as the final output [9]. Therefore, the process parameters of hot-melt extrusion should be
accustomed based on the physicochemical properties of each formulation component.
Theoretically, as a rule the temperature of extrusion is required to set at 10-20 °C above the Tg of
the polymers for flow consideration during the extruding process. In addition, there are many
properties that could also be critical in HME process such as the melt viscosity of polymer,
molecular weight, and miscibility. Furthermore, the plasticization effect of the drug on polymer
may also plays an important role in extrudability of materials [16]. Many research studies have
shown that the P-CO2 behaves as a plasticizer for some pharmaceutical polymers[17,23–
25,30,31].
In this study, the temperature of extrusion and drug/polymer ratio have a major influence
on HME process. During early stage of HME process optimizing, the extrudability of plain pure
polymer was impossible when we set the temperature of the extruder below 160 °C since it led to
reach the maximum level of motor load. At 160, 165, and 170 °C, the motor load was almost at 96
%. This could be attributed to high viscosity of the polymer. To reduce the motor load, the speed
of extruder was lowered to 75 rpm at all temperatures studied. The processing enhancement was
very limited, and the process was restricted to go further. Moreover, P-CO2 did not indicate any
sign of plasticizing effect on the polymer (reduction in the HME processing temperature and motor
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load). Therefore, it was not logical to inject the P-CO2 at such high motor load. Quite the contrary,
it exhibited rise in motor load even with increasing the temperature of extruder which would be
explained as inability of the P-CO2 stream to penetrate the polymer. The relationship between the
polymer, P-CO2, and temperature directed to inject the P-CO2 only at zone 8; neither zone 6 nor
zone 4, which was very difficult to apply into the HME process. Table 2 lists the results of this
relationship. Zone 4 and zone 6 provide relatively a long period of contact between the polymer
and P-CO2 until they reach the extruder die. At zone 8 (Figure 1), the polymer and P-CO2 meet
only at zone nine and ten of the extruder. Additionally, at zone 4 & 6 (Figure 1), the chance of
back-pressure issue in extruder is high, which spread materials out of the feeding zone. However,
it would be possible to inject the P-CO2 at least at zone 6 with increasing temperature to above
190 °C. Nevertheless, the high temperature is not practical and having undesirable consequences
upon formulation components and the extruder parts. Injection of P-CO2 at zone 8 was desirable
to successfully produce a foaming, porous extrudates (Figure 1).
3.2. Screening of appropriate API

The type of drug, and its ratio in the formulations was very critical during the optimizing
of the HME process. The low melting point drugs were supposed to be a suitable choice since
those drugs could melt at low temperature and might act as plasticizing agents for HPMC-AS LG
and provide smooth HME processing. Ibuprofen (Tm is about 78 °C) as a model drug provided a
plasticizing effect as it was expected for the goal that it was selected for. However, the accumulated
sticky materials caused a blockage at the feeding zone which is because of the low Tm of ibuprofen.
Consequently, these sticky materials hindered obtaining a continuous HME process. It was
concluded that not all low-melting point drugs act as plasticizers to HPMC-AS LG while injection
of P-CO2. It was clearly observed that the steam of P-CO2 became hot after getting inside the
11

barrel, beside the temperature of extruder, which facilitated melting of ibuprofen and accumulating
at the neck of funnel in the feeding zone. Additionally, a high melting point drug was investigated
to avoid the blockage issue at the feeding zone. Theophylline (Tm is around 273 °C) was studied
while HME processing. The initial results displayed that there is no blockage at the neck of the
funnel at the feeding zone while processing theophylline through the HME. In the other hand,
theophylline did not demonstrate significant persuasive impact on the HME process, because the
motor load was high, even with the extruder temperature set up at 165 °C. This explains that there
is no plasticizing effect of theophylline on HPMC-AS LG. Thus, intermediate melting point drug
EFA (Tm is about 138 °C) was selected as the main model drug in this study. EFA showed very
impressive influence on HPMC-AS LG via HME process. It overcame the blockage issue at the
feeding zone and provided a strong plasticizing effect on HPMC-AS LG even with low ratio within
the formulations (Table 2). While increasing the ratio of EFA, the motor load was going down,
which means very desirable plasticizing effect without causing any blockage at the feeding zone
during the HME process. With such an influence, the HME process would have a high range of
flexibility and capacity to control the process for reaching the optimizable conditions. Moreover,
The great character of polymers when they prove the high ability to solubilize a large amount of
drug [32]. HPMC-AS LG has demonstrated its excellence by dissolving 50% of EFA in complete
amorphous state as confirmed by DSC, and PXRD studies.
3.3. Drug content and degradation

TGA data demonstrated that all formulations utilized in this study were stable under the
employed processing temperature (data not shown). UV analysis indicated acceptable uniformity
of drug and drug content and no degradation of EFA as a function of temperature and pressure
during the hot melt extrusion process with and without carbon dioxide injection. This confirmed
12

that the EFA was uniformly distributed in formulations with a higher yield. The combined HME/PCO2 processes showed relatively lower process loss. The average weights (± SD) of two series of
20 capsules contents is equivalent to 100 mg of EFA. The reproducibility indicated by these results
were considered to be satisfactory for the purposes of the present study. The analysis of drug
content confirmed the theoretical value of the formulations, with values ranging from 96% to
102%.
3.4. Differential scanning calorimetry (DSC)

DSC studies were conducted on all formulations including pure EFA and HPMC-AS LG,
to ascertain the impact of P-CO2 during the processing of formulations and if it had any effect on
their thermal properties.
As it can be seen in Figure 2, the DSC thermograms of pure EFA showed apparent
endothermic peak at around 140 °C. The sharp EFA peak was disappeared in all processed
formulations except for their respective physical mixtures which shows less endothermic peak
(less Tm) with less enthalpy of fusion. The absence of the peak indicates that the all processed
formulations preserved the amorphous nature after HME coupled with P-CO2 processing.
3.5. Powder X-ray Diffraction Measurements (PXRD)

The diffraction patterns Figure 3 obtained from pure EFA, pure HPMC-AS LG, all processed
formulations and their respective physical mixtures

confirmed the amorphous nature of

EFA and is in accordance with DSC data. Analysis of the XRD pattern obtained from pure EFA
sample showed the several crystal peaks including the characteristic sharp and intense peak of
EFA. As shown in Figure 3, the X-ray diffraction patterns of various samples, including processed
extrudates, physical mixture (PM), and pure API showed characteristic peaks attributed to its
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crystalline nature of EFA structure. On the other hand, the diffraction pattern of pure HPMC-AS
LG did not show any Peaks (hallow band), which indicates that its polymeric structure is
amorphous. In the physical mixture of EFA and HPMC-AS LG, there still were less intense peaks
due to presence of partial EFA in crystalline form. In the X-ray pattern of the EFA–HPMC-AS LG
extrudates, showed absence of characteristic peaks indicating the transformation of crystalline
EFA into amorphous form and suggests that EFA was present in amorphous state. Finally, the
diffractograms of the processed formulations before and after P-CO2 treatment assured that no
modifications occurred after the treatment.
3.6. Dissolution Studies

To investigate the influence of P-CO2 injection within the polymeric matrix on EFA release from
the HPMC-AS LG extrudates, In-Vitro dissolution study was conducted. HPMC-AS LG
demonstrated enhancement of EFA dissolution rate, which is unidirectional to the increasing
percentage of HPMC-AS LG in the formulations. Figure 4 shows the dissolution of EFA from
various extrudates in the dissolution medium (pH 6.8). Extrudates at all drug loads released EFA
higher than the pure EFA, presumably by generating a supersaturated state in the dissolution
medium. The formulation of 30% EFA / HPMC-AS LG which processed by the assistance of PCO2 showed relatively greater EFA release than the other formulations (40%, 50% EFA / HPMCAS LG). This can be attributed to the media which is more specified for the HPMC-AS LG
polymer and presence of polymer in a high percent. The order of improvement of drug dissolution
for the formulations processed by this coupled technology (HME/P-CO2) was 30% EFA / HPMCAS LG EXT/ P-CO2> 40% EFA / HPMC-AS LG EXT/ P-CO2> 50% EFA / HPMC-AS LG EXT/
P-CO2.
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Table 2. Results and conditions of investigating the extruder parameters, (polymer/ drug) ratio, and the type of the drug on HME
processes with and without P-CO2 injection.
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Formulations

Processing
Temperature
(°C)

Screw
Speed
(rpm)

Barrel
Torque
(%)

100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
100% HPMC-AS LG
80% HPMC-AS LG/% 20 EFA
70% HPMC-AS LG/% 30 EFA
60% HPMC-AS LG/% 40 EFA
50% HPMC-AS LG/% 50 EFA
80% HPMC-AS LG/% 20 EFA
70% HPMC-AS LG/% 30 EFA
60% HPMC-AS LG/% 40 EFA
50% HPMC-AS LG/% 50 EFA
80% HPMC-AS LG/% 20 EFA
70% HPMC-AS LG/% 30 EFA
60% HPMC-AS LG/% 40 EFA
50% HPMC-AS LG/% 50 EFA
80% HPMC-AS LG/% 20 EFA
70% HPMC-AS LG/% 30 EFA
60% HPMC-AS LG/% 40 EFA
50% HPMC-AS LG/% 50 EFA

140
140
140
140
150
150
150
150
160
160
170
170
190H.T
190H.T
190H.T
190H.T
140
140
140
140
150
150
150
150
140
140
140
140
150
150
150
150

100
75
100
75
100
75
100
75
100
75
100
75
100
75
100
75
100
100
100
100
75
75
75
75
100
100
100
100
75
75
75
75

Maximum *
Maximum
Maximum
Maximum
Maximum
Maximum
Maximum
Maximum
98H.Q
88H.Q
88-90H.Q
82H.Q
84-92H.Q
80-90H.Q
84-92H.Q
80-90H.Q
54
46
33
27
44
25-30
20-25
13-20
54
46
33
27
44
25-30
20-25
13-20

P-CO2
Injection Zone
4
-

6
-

8
√
√
√
√
√
√
√
√
√
√

P-CO2
(PSI)

Back
Pressure

Feeding
Zone
Blockage

HME
Process

300-400
300-400
300-400
300-400
300-400
300-400
250-350
250-350
250-350
250-350

Low
Low
Low
Low
Low
low
Low
Low
Low
Low

No
No
No
No
No
No
No
No
No
No

Failed
Failed
Failed
Failed
Failed
Failed
Failed
Failed
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful
Successful

*The motor reached the maximum level that was impossible to move on.
Very limit success which means obtaining final product, but under very high motor load and temperature.
H.T: very high temperature.
H.Q: very high the motor load.

Pure EFA
Pure HPMC-AS LG
30% EFA/70% HPMC-AS LG PM
40% EFA /60% HPMC-AS LG PM
50% EFA /50% HPMC-AS LG PM

30% EFA/70% HPMC-AS LG EXT

40% EFA/60% HPMC-AS LG EXT

50% EFA/50% HPMC-AS Lg EXT
30% EFA /70% HPMC-AS LG EXT+P-CO2
40% EFA /60% HPMC-AS LG EXT+P-CO2
50% EFA /50% HPMC-AS LG EXT+P-CO2

Figure 2. DSC thermograms of pure EFA, pure HPMC-AS LG, physical mixtures (PM) and extrudates (EXT) (with
and without P-CO2).

Interestingly, even though that the number of pores within the extrudates is higher and larger in
50% drug load formulation (Figure 5) which might facilitate the drug release, but this can’t be
compromised by the media which is highly preferable by the polymer. Furthermore, it was
observed that HPMC-AS LG substitution level (LG grade) plays an important role in enhancing
the solubility of EFA, which released faster and more completely from the EFA / HPMC-AS LG
-grade extrudates (Figure 4). This result stems from EFA’s higher lipophilicity (logP of 4.6), which
makes it dissolution-rate-limited, and from the higher succinoyl content of the LG-grade polymer,
which offers higher hydrophilicity and thereby improves the dissolution rate. The same
phenomenon has happened with a previous study.
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Figure 3. A: PXRD diffractograms of pure crystalline EFA, B: PXRD diffractograms of pure HPMC-AS LG. C, F,
and I: PXRD diffractograms of %30, %40, and %50 EFA/ HPMC-AS LG PM. D, G, and J: PXRD diffractograms of
%30, %40, and %50 EFA/ HPMC-AS LG without-CO2. E, H, and K: PXRD diffractograms of %30, %40, and %50
EFA/ HPMC-AS LG with P-CO2.

The dissolution profiles are relatively higher for the CO2-treated materials. These extrudates were
all amorphous, indicating that the release can be controlled as a function of the carbon dioxide
treatment [25]. It was found that the HPMC-AS LG matrix governs the dissolution rate of the
extrudates. When the molecules of HPMC-AS LG were dissolved, the EFA molecules dissolved
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simultaneously because EFA molecules (up to 50%) were in amorphous form as shown in Figure
2 and there was no need to overcome the lattice energy. Therefore, it has been confirmed that EFA
was molecularly dispersed or nearly molecularly dispersed in the HPMC-AS LG matrix.
The dissolution rate depends on the surface area of the material exposed to the dissolution
media [33]. Although the foamed extrudates exhibit an increased surface area, the unmilled foams
had significantly slower dissolution than regular ground extrudates.
Moreover, although the porous matrix exhibited high surface area, the P-CO2 processed
formulation (50% EFA / HPMC-AS LG) that has the lower density value and higher porosity
(Table 3), and larger pore size (Figure 5-P, Q, R) has almost the same dissolution profile as the
formulation without P-CO2 treatment (regular extrudates). This could be attributed to the particles
being floated and accumulated on the surface of the media making these particles not fully
accessible to all sides of the media resulting in limited contact between the two phases. Moreover,
this can be attested by visually noticing the floating particles on the media surfaces throughout the
dissolution study.
In contrast, the other formulations; the P-CO2 processed formulations (30 & 40% EFA /
HPMC-AS LG) sank into the dissolution media allowing the dissolution process to proceed faster
through the fully accessible surfaces[34]. Since the P-CO2-treated extrudates are more
hygroscopic[25], water penetrates faster within the matrix whereas slower in regular extrudates.
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Figure 4. In-Vitro release profile extrudates with and without P-CO2

3.7. Scanning electron microscopy (SEM)

The surface of all processed extrudates with P-CO2 treatment, shown in the SEM images
of Figure 5, is quite different to the ones made by traditional extrusion process in which the
extrudate is smooth compared to the foamed and porous extrudates. The specific surface area is
clearly larger in the case of the foamed samples providing extended availability to the dissolving
medium, which may increase the dissolution rate[34]. The internal and external porous structures
of solid dispersions as seen in Figure 5 can alter the physico-mechanical properties of such a
formulation.
On the other hand, as shown in Figure 5, the matrix had mesh-like framework, denoting
that P-CO2 penetrated during the process uniformly through HPMC-AS LG matrix. Thereby, these
images suggest that homogeneous or heterogeneous porosity behavior might occur depending on
drug load; i.e. with an increase in drug load up to (50%), homogeneous pores are formed during
the processing of dispersions assisted by P-CO2 treatment while in (30% drug load), heterogeneous
pores are formed during the processing of dispersions assisted by P-CO2 treatment. These pores
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are dominating structures of HPMC-AS LG matrices. This can be attributed to the plasticizing
effect of EFA, which leads to less viscous matrices and facilitate the penetration of P-CO2
homogeneously throughout the matrix within the extruder barrel[34]. This can be confirmed by
seeing images of regular extrudates wherein the smoother surfaces are accompanied with higher
drug load (50%) whereas the rougher surfaces are accompanied with less drug load 30%. The
smoothness of surfaces is a sign of the plasticizing effect of EFA on the polymer. This is in
accordance with previous reports[23,35]. After injecting P-CO2 during the hot melt extrusion
process and while the materials are exciting the extruder die, the pressure is expanded to
atmospheric conditions, thereby, P-CO2 is released from the extrudates. This results in foam
formation as explained by Lee et al.[36] and Park et al.[37]. Also, they illustrated that the pore size
can be altered as a function of CO2 pressure and temperature. In addition, they obtained different
morphologies ranging from a foamy-like structure to a fibrous-like structure[24].

3.8. Density and Porosity

As seen in Table 3, all density values were decreased in case of formulations prepared by
the aid of P-CO2. This would occur because of foamy and porous matrices that have been formed
after P-CO2 treatment. Furthermore, porosity values are higher with samples prepared by the aid
of P-CO2. This would allow for large surface area which leads to improved dissolution profile as
well as tablet characteristics [23]. Also, it leads to high surface free energy that aids in stabilizing
the amorphous form[38–41]. This low density and porous matrices might help in tablet
characteristics which would be the theme of a continuing study.
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Table 3. Bulk, tapped, true density and porosity of pure EFA, pure HPMC-AS LG, Physical
Mixture (PM) and Extrudates (EXT) with and without P-CO2 (g/ml)
Sample Name
EFA
HPMC-AS LG
30% EFA / HPMC-AS LG PM
40% EFA / HPMC-AS LG PM
50% EFA / HPMC-AS LG PM
30% EFA / HPMC-AS LG EXT
40% EFA / HPMC-AS LG EXT
50% EFA / HPMC-AS LG EXT
30% EFA / HPMC-AS LG EXT+P-CO2
40% EFA / HPMC-AS LG EXT+P-CO2
50% EFA / HPMC-AS LG EXT+P-CO2

Bulk
Density
0.225
0.462
0.369
0.351
0.317
0.598
0.612
0.620
0.461
0.494
0.350

Tapped
Density
0.338
0.470
0.447
0.421
0.404
0.629
0.668
0.652
0.493
0.519
0.466

True
Density
1.450
1.289
1.416
1.474
1.532
1.347
1.362
1.381
1.350
1.357
1.382

%porosity
84.440
64.164
73.912
76.192
79.261
55.631
55.066
55.111
65.874
63.617
74.681

3.9. Milling Efficiency

Influence of P-CO2 on milling efficiency for foamy structure extrudate was evaluated. Regular
extrudates (i.e. without P-CO2 treatment) are glassy form in nature, which make them very difficult
to mill to obtain a suitable particle size distribution. Consequently, the milling efficiency was
determined with and without P-CO2 injection within HME process. Table 4 displays the results for
this investigation. These results confirmed that the obtained amount of selected particle sizes
(<600, 250, and 125 um) after milling process for formulation with P-CO2 larger than the
corresponding formulations without P-CO2. Moreover, the resistance of milling machine during
milling process for formulations with P-CO2 was less than the corresponding formulations without
P-CO2. The enhancement of milling efficiency would be due the morphology changes into foamlike structure extrudates, as impact of P-CO2 injection.
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Figure 5. SEM images of all Extrudates without, and with P-CO2; A, B, and C 30 % Extrudate (30% EFA / 70%
HPMC-AS LG without P-CO2), D, E, and F 30 % Extrudate (30% EFA / 70% HPMC-AS LG with P-CO2), G, H,
and I 40 % Extrudate (40% EFA / 60% HPMC-AS LG without P-CO2), J, K, and L 40 % Extrudate (40% EFA /
60% HPMC-AS LG with P-CO2), M, N, and O 50 % Extrudate (50% EFA / 50% HPMC-AS LG without P-CO2),
P, Q, and R 50 % Extrudate (50% EFA / 50% HPMC-AS LG with P-CO2)
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Table 4. Results of the Milling Efficiency
Sample Name

Torque
(Amps)

Particles <
600 um
(%)

Particles <
250 um
(%)

Particles <
125 um
(%)

30% EFA / HPMC-AS LG EXT

1.08

78.44

9.57

1.03

40% EFA / HPMC-AS LG EXT

0.85

84.99

15.33

2.74

50% EFA / HPMC-AS LG EXT

0.79

77.90

3.37

0.98

30% EFA / HPMC-AS LG EXT P-CO2

0.79

92.14

14.88

1.97

40% EFA / HPMC-AS LG EXT P-CO2

0.74

97.70

24.41

4.75

50% EFA / HPMC-AS LG EXT P-CO2

0.72

98.08

13.64

1.79

Conclusion
The comprehensive understanding of the relationship between the physico-chemical
properties and physico-mechanical properties for physical mixtures of medium melting point EFA
and higher Tg HPMC-AS LG, as well as the correlation with the actual hot-melt extrusion process
parameters, and impact of P-CO2 successfully leads to obtain high-loading EFA within plasticized
foamy matrix as a final output. HPMC-AS LG improved the release profile for all EFA-loaded
extrudates with and without P-CO2 injection. However, EFA-loaded extrudates with P-CO2
revealed relatively higher drug release than extrudates without P-CO2. The morphologic changes
of extrudates as a foam-like structure after P-CO2 injection, resulting in an increased surface area
and porosity. Thus, the milling efficiency of the extrudates was improved. HPMC-AS LG
demonstrates a promising carrier to produce physically and chemically stable amorphous solid
dispersion systems which are processed by HME.
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